Hyperbaric Oxygen Therapy (HBOT) for Stage IV Cancer
Also known as: HBOT, HBO, Hyperbaric medicine
HBOT reverses tumor hypoxia — a key driver of treatment resistance, angiogenesis, and metastasis.
Mechanism of Action
Tumor hypoxia activates HIF-1α, driving angiogenesis, EMT, and treatment resistance. HBOT increases tumor oxygenation, enhancing radiation sensitivity (oxygen enhancement ratio), improving chemotherapy delivery, and potentially enhancing immunotherapy through reduced immunosuppressive hypoxic signaling.
General mechanism: Pressurized oxygen delivery. Hyperoxia/normoxia cycling activates HIF pathway, stem cell mobilization, angiogenesis, anti-inflammatory signaling.
Current Evidence
Meta-analyses show HBOT enhances radiation therapy for head/neck cancer. Reduces radiation late effects. Sensitization of hypoxic tumors to treatment documented. Combination with immunotherapy being studied.
Clinical Status: Established for radiation injury treatment. Radiation sensitization evidence strong.
Safety Profile
Generally safe. Ear/sinus barotrauma, oxygen toxicity seizures (rare). Contraindicated with untreated pneumothorax. Specialized facility required.
Key Research Questions
- Can HBOT enhance immunotherapy by reversing tumor hypoxia-driven immunosuppression?
- Does HBOT improve chemotherapy delivery to hypoxic tumors?